Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple ...

Sunday, Sanofi SA’s (NASDAQ:SNY) data from the HERCULES phase 3 study showed that tolebrutinib met the primary endpoint of ...

Sanofi has bolstered the case for its oral BTK inhibitor tolebrutinib as a treatment for multiple sclerosis (MS), due to be filed for approval in the latter half of this year, with new data in a ...

Sanofi said the GEMINI 1 and 2 trials of tolebrutinib in relapsing forms of MS are fully enrolled and should read out in time to meet its plan of filing for regulatory approval in the US in 2024.

The recent results of tolebrutinib in non-active secondary progressive MS presented at the ECTRIMS 2024 conference, reinforce the scientific hypothesis that targeting microglia in nSPMS is a valid ...

A key focus will be the results from large phase 3 trials of BTK inhibitors such as tolebrutinib, which are eagerly anticipated by the MS community. Additionally, there may be discussions on ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple ...

The primary endpoint of the study is the effect of masitinib on time to confirmed disability progression. The recent results of tolebrutinib in non-active secondary progressive MS presented at the ...